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Update to evidence-based guide  
to smoking cessation therapies  
Faraz Siddiqui, Rumana Huque and Omara Dogar 
Abstract
Despite a general decline in smoking rates in the UK, smoking 
prevalence remains high among young adults, pregnant women 
and those from socioeconomically disadvantaged backgrounds. 
These three groups are also more likely to benefit from targeted 
smoking cessation interventions. Clinical contact between health 
professionals and patients who smoke creates an opportunity for 
offering cessation interventions and to reduce smoking-related harm. 
This article summarises evidence, based on high-quality systematic 
reviews, on smoking cessation interventions that could be offered 
by health professionals coming in to contact with patients who 
smoke. The evidence presented here suggests that brief advice by 
a health professional is beneficial in achieving smoking cessation 
and so is intensive behavioural support alone or in combination 
with pharmacotherapies (nicotine replacement therapies (NRTs), 
bupropion and varenicline). Pharmacotherapies are also effective 
individually in promoting smoking cessation; a combination of 
NRTs (oral or skin patch) can be particularly helpful in promoting 
cessation among highly dependent smokers. Pharmacotherapies 
in combination with behavioural support delivered in health care 
settings are more effective than when used alone and delivered in 
community settings, respectively.
Key words: Smoking cessation; cessation therapies; behavioural 
support; pharmacotherapies
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Currently, the proportion of adult smokers in the UK has halved (19%) down from a peak of 46% 
in 1970s. he proportion of men aged 16 and above 
who smoked cigarettes was 20% whereas 17% of 
women  smoked in 2014 (Oice for National Statistics 
(ONS), 2014). More than twice as many people 
in socioeconomically disadvantaged areas smoke 
compared to those in aluent areas (33.8% vs 14.1%) 
(Simpson et al, 2010). he phenomenon remains 
consistent in adolescents; the odds of smoking among 
adolescents living in the UK are also seen to increase 
with increasing area-level deprivation (Levin KA et al, 
2014). In men, more than half of the risk of premature 
mortality between social classes is secondary to tobacco 
smoking (Jarvis and Wardle, 1999). Furthermore, two 
thirds of deaths among women who smoke are due to 
smoking itself; resulting in a loss of at least 10 years of 
average lifespan (Pirie et al, 2013). However, 90% of 
deaths due to smoking can be avoided if a person quits 
before the age of 40 years; if before the age of 30, 97% of 
excess deaths can be avoided (Pirie et al, 2013). 
Smoking cessation
Given that smoking is the single most preventable 
cause of premature mortality (Jha et al, 2006), the UK 
government has introduced a range of initiatives, such 
as the UK stop smoking services, in recent decades 
to reduce smoking related deaths (Bauld et al, 2016). 
Between 2001 and 2007, access to specialist advice 
on smoking cessation increased from 43.6% to 84.0% 
(Simpson et al, 2010) and data from stop smoking 
services in England show that 35% of service users 
achieve abstinence four weeks ater quitting (West 
et al, 2013). he long-term quit rate (52 weeks ater 
quitting) of smokers who try to quit on their own is 
approximately 3% (Hughes et al, 2004) which is lower 
than the quit rate seen in the English stop smoking 
services (8%) and particularly lower than those of the 
specialist one-to-one and group services (10% (95% 
CI 8–11%) and 12% (95% CI 11–14%), respectively) 
(Bauld et al, 2016). However, comparatively higher 
rates of smoking are still found among younger adults 
(Levin KA et al, 2014), pregnant women (Meernik 
and Goldstein, 2015) and those who are the most 
socioeconomically disadvantaged (Hiscock et al, 
2012), including ethnic minorities (Liu et al, 2012). 
If targeted appropriately, these groups are most likely 
to beneit from Stop Smoking Services. he highest 
quit rates in the UK were found among those from 
socioeconomically deprived areas (7.2%) and young 
adults (16–25 years: 7.1%) (Simpson et al, 2010). 
Around 45% of women tend to stop smoking either just 
before or during their pregnancy (Woodby et al, 1999); 
however, only a third are able to maintain continuous 
abstinence ater a year (Centers for Disease Control and 
Prevention (CDC), 2002). 
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Table 1. An evidence-based guide to smoking cessation therapies  
in practice
Sufficient evidence/ 
definitely beneficial
Brief advice by trained professionals in health care settings over no advice
Individual behavioural therapy by trained health workers over brief advice
Group behavioural therapy over self-help materials
Nicotine replacement therapies (NRTs) over placebo in smokers motivated to quit
Combination of NRTs (skin patches and oral forms) among heavy smokers over single NRT
Varenicline (standard dose), bupropion, nortryptyline and cytisine over placebo
Varenicline (low dose) over placebo with fewer side effects 
Varenicline over buproprion and single NRT 
Combinations of behavioural support and pharmacotherapies over brief advice or usual care 
Combination therapy of behavioural support and pharmacotherapy in health care settings vs 
community-based settings
Intensive behavioural support as an adjunct to pharmacotherapy
Increasing intensity of behavioural support in people using pharmacotherapies over same level of 
intensity
Insufficient 
evidence/ probably 
beneficial
Individual intensive behavioural support over less intense behavioural interventions
Group behavioural support interventions over brief advice
NRT use among lighter smokers (<10–15 cigarettes per day) over placebo
NRT use pre-quit over NRT starting on quit day
NRT vs placebo in smokers who are not willing to quit
NRT for longer duration or in higher concentrations compared to standard use
Use of nicotine patches beyond 8 weeks of therapy
One form of NRT over another
NRT or partner support in pregnancy
Varenicline over placebo for relapse prevention 
Combination of behavioural support with varenicline or nortriptyline 
Nicotine assisted reduction to stop (NARS) vs abrupt cessation
E-cigarettes vs non-nicotine placebo 
Unknown evidence/ 
unknown benefit
Group behavioural therapy over individual behavioural therapy
Varenicline or bupropion use in pregnancy
Smoking cessation by health 
care providers 
he majority of smokers who wish to quit ind it 
very diicult to give up on their own without proper 
professional support, leading them to several futile quit 
attempts (Fiore, 2000). hose attending Stop Smoking 
Services are four times more likely to give up their 
smoking habit successfully than those attempting to 
quit on their own (National Institute for Health and 
Care Excellence (NICE), 2008). Generally, 79–90% of 
smokers are willing to quit (National Institute of Health 
(NIH) State-of-the-Science Panel, 2006) and 70% of 
them visit a health professional to seek relevant support 
(Cherry et al, 2003). Nurses, the largest group of 
health professionals involved in the majority of clinical 
contacts, have an opportunity to inluence the smoking 
behaviour of their patients and reduce smoking-related 
harm (Percival et al, 2003; Whyte and Kearney, 2003). A 
recent systematic review found a signiicantly profound 
efect of nurse-delivered interventions on increasing the 
likelihood of quitting among patients who smoked (RR 
1.29, 95% CI 1.20-1.39) compared to control or usual 
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care (Rice et al, 2013). 
he NICE guidelines for health professionals 
recommend using a range of smoking cessation 
‘interventions’ and activities, including pharmacological 
(nicotine replacement therapy (NRT), bupropion 
and varenicline) as well as non-pharmacological 
(behavioural therapies) options (NICE, 2008). 
his article ofers a practical, accessible and 
evidence-based guide on smoking cessation therapies 
for nurses providing health care in a variety of settings. 
It summarises evidence from a relevant Cochrane 
reviews on smoking cessation interventions, in line with 
the NICE recommendations (2008) and contemporary 
views on behavioural change theories and techniques 
(BCTs). Table 1 summarises the evidence.
Defining quit
Smoking cessation experts have deined speciic criteria 
as follows, referred to as the Russell standard, to 
conirm when a smoker is considered to have quitted 
(West, 2005):
A ‘self-reported 4-week quitter’ is a treated smoker 
assessed (face-to-face, by postal questionnaire or by 
telephone) 4 weeks ater the assigned quit date who 
declares that s/he has not smoked even a single puf of a 
cigarette in the past 2 weeks
A ‘carbon-monoxide (CO) veriied 4-week quitter’ is 
a self-reported 4-week quitter and his/her expired-air 
CO is assessed 4 weeks ater the assigned quit date and 
found to be less than 10 ppm
A ‘52-week quitter’ is a treated smoker assessed 
(face-to-face, by postal questionnaire or by telephone) 
52 weeks ater the designated quit date and declares that 
s/he has not smoked more than ive cigarettes in the 
past 50 weeks.
Smoking cessation therapies  
in health care practice 
Brief interventions
Brief interventions by a health professional include 
opportunistic advice, discussion, negotiation or 
encouragement and, where necessary, referral to a 
specialist service, typically lasting less than 10 minutes 
(NICE, 2008). 
Compared to no advice, brief advice by practitioners 
(physician or physician supported by other health 
care workers) to smokers increases the likelihood of 
successful quit attempts at 6 months (RR 1.66, 95% CI: 
1.42–1.94). Assuming an unaided smoking cessation 
rate of 2–3%, brief advice can increase the cessation rate 
by a further 1–3% (Stead et al, 2013). 
Behavioural support interventions/counselling 
(individual or group)
Behavioural support interventions are delivered 
through face-to-face consultations (‘individual 
behavioural therapy’) or consultations in groups 
(‘group behavioural therapy’) consisting of weekly 
appointments for the irst 4 weeks of a quit attempt, 
where the smokers receive information, advice and 
encouragement and some form of behavioural change 
intervention (NICE, 2008). ‘Group behavioural therapy’, 
in addition to applying behavioural change techniques, 
ofers an opportunity for social learning and mutual 
support (Stead and Lancaster, 2005). Telephone 
counselling and quitlines are also used to support those 
who are considering quitting, and those who have 
recently quitted (NICE, 2008).
Individual behavioural therapy
Individual behavioural therapy oten takes the form 
of advice, discussion, encouragement and activities to 
help people stop smoking successfully. hese activities 
are designed to change targeted behavioural patterns, 
involving three essential conditions: capability, 
opportunity and motivation—core to the framework 
of the ‘behavioural system’ (Michie et al, 2011a). he 
‘active ingredients’ of behavioural support interventions 
are classiied into four functions:
 ■ Directly addressing motivation, e.g. by providing 
rewards dependent on abstinence
 ■ Maximising self-regulatory capacity, e.g. facilitating 
barrier identiication and problem solving
 ■ Promoting adjuvant activities, e.g. advising on stop-
smoking medication
 ■ Supporting other BCTs, e.g. building general rapport 
(Michie et al, 2011b). 
In total, 43 such behavioural change techniques 
have been identiied for this purpose (Michie et al, 
2011b) and should form the core of behavioural support 
interventions for smoking cessation.
Behavioural support interventions delivered via 
face-to-face sessions by a trained health care worker 
achieved higher success rates in quitting at 6 months 
(RR 1.39, 95% CI: 1.24–1.57) compared to brief 
interventions delivered by health workers other 
than nurses and doctors. he behavioural support 
interventions, typically involving intensive counselling 
for more than 10 minutes, included a review of 
the smoking history and the motivation to quit, 
identiication of high-risk situations, and proposing 
problem-solving strategies to cope with such situations 
(Lancaster and Stead, 2005). However, when individual 
behavioural support interventions were compared to 
brief interventions, irrespective of who is delivering 
these, there was insuicient evidence to support any 
marginal beneit (ive trials, RR 0.96, 95% CI: 0.74–
1.25) (Lancaster and Stead, 2005). 
Group behavioural therapy
Group therapies consist of information, advice and 
encouragement over several sessions. Such therapies are 
likely to double the chances of cessation among smokers 
compared to self-help materials alone (RR 1.98, 95% CI: 
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1.60–2.46) (Stead and Lancaster, 2005). However, there 
is limited evidence on whether adding group therapies 
to brief interventions received from health professionals 
produced any extra beneit (Stead and Lancaster, 2005).
here is also not enough evidence to suggest whether 
group behavioural therapies are more (or less) efective 
or cost-efective than individual behavioural therapies 
(Stead and Lancaster, 2005).
Nicotine replacement therapy 
Mode of action
Of all tobacco ingredients, nicotine is the most 
addictive, but perhaps least harmful substance. 
herefore, nicotine replacement therapy (NRT) 
is a highly attractive cessation tool, as it reduces 
motivation to smoke by countering the physiological 
and psychomotor efects of nicotine withdrawal, 
easing the transition to sustained abstinence (West 
and Shifman, 2001). Commercially-formulated NRTs 
are absorbed either through the skin, in the form 
of transdermal patches, or through oral mucosa, in 
the form of chewing gum, nasal spray, inhalers and 
lozenges/tablets, all of which deliver nicotine more 
quickly than patches, but less quickly than cigarettes.
All commercially available forms of NRT increase 
the likelihood of smoking cessation by about 50–70% 
(RR 1.60, 95% CI: 1.53–1.68) compared to placebo or 
non-NRT controls (Stead et al, 2012). he relative risks 
of smoking cessation for various forms of NRT are: 
nicotine gum 1.49 (95% CI: 1.40–1.60), nicotine skin 
patch 1.64 (95% CI: 1.52–1.78), nicotine inhaler 1.90 
(95% CI: 1.36–2.67), tablets and lozenges 1.95 (95% 
CI: 1.61–2.36) and nicotine nasal spray 2.02 (95% 
CI: 1.49–2.73) independent of the duration of use, 
intensity of any additional behavioural support or the 
delivery settings (Stead et al, 2012).
Combinations of nicotine skin patches and oral 
NRTs can signiicantly increase the chances of 
successful cessation attempts among heavy smokers 
(RR 1.34, 95% CI: 1.18–1.51) compared to using a 
single type alone (Stead et al, 2012).
Initiating NRT use shortly before setting the quit 
date does not signiicantly increase the chances of 
successful cessation among smokers (RR 1.18, 95% CI: 
0.98–1.51), compared to starting NRT on the quit date 
(Stead et al, 2012). Moreover, the evidence is limited 
on the usefulness of NRTs in increasing the chances of 
successful quitting among those who smoke less than 
10–15 cigarettes in a day. 
Dosing
Skin patches of NRT are available in several diferent 
doses, and can deliver up to 44 mg of nicotine over a 
16- or 24-hour period, with optimal results achieved 
for 25 mg patches (Stead et al, 2012). Application 
of NRT skin patches for extended durations does 
not suggest a diference in cessation rates; however, 
both 16 vs 24 hour application methods are efective 
for smoking cessation when compared to a placebo. 
Nicotine lozenges and nicotine chewing gum are 
available in both 2 mg and 4 mg strengths. here 
is limited evidence on any remarkable diference 
between the various forms of NRT or its use beyond 8 
weeks of therapy (Stead et al, 2012). Heavier smokers, 
highly dependent on nicotine, might beneit from a 
higher dose of nicotine gum (4 mg compared to  
2 mg), but the evidence is weak in proposing the 
beneits of using higher doses of nicotine patch (Stead 
et al, 2012).
Side efects
he use of NRT is considered relatively safe with 
minor adverse efects reported. hese include skin 
sensitivity and irritation in patch users, afecting 
around 54% of users (Fiore et al, 1992), buccal 
mucosal irritation, hiccoughs, jaw pain and orodental 
problems from gum and tablets, and local irritation 
at the site of administration from nicotine inhalers 
and nasal sprays (Stead et al, 2012). here is lack of 
evidence to support that NRT increases the risk of 
cardiovascular events, cancers, stroke or reproductive/
developmental efects (Lee and Fariss, 2016); however, 
a signiicant association with heart palpitations and 
chest pain (RR 1.88 95% CI 1.37–2.57) has been 
observed with its use (Stead et al, 2012).
Other pharmacotherapies
Varenicline and bupropion are two popular forms of 
pharmacotherapies used to aid smoking cessation in 
practice. In addition, newer drugs like nortriptyline 
and cytisine have also been used recently. 
Mode of action
When smokers quit, they experience cravings to 
smoke and unpleasant mood changes due to the 
nicotine withdrawal. Varenicline is a nicotine receptor 
partial agonist that aims to reduce such symptoms. 
It counteracts the efects of nicotine on the neuronal 
acetylcholine receptors (nAChRs), based on the 
naturally occurring alkaloid compound cytisine 
(Papke and Heinemann, 1994; Slater et al, 2003). 
Nicotine withdrawal might precipitate depression, as 
nicotine appears to have anti-depressive properties. 
Bupropion (an anti-depressant) can substitute for 
this efect by inluencing the neurotransmitters and 
receptors involved in nicotine addiction (Benowitz 
and Peng, 2000; Kotlyar et al, 2001).
Nortriptyline (a tricyclic antidepressant) is 
believed to increase noradrenergic activity; it may 
be prescribed when irst-line treatments have been 
unsuccessful (Hughes et al, 2014).
Bupropion and nortriptyline both signiicantly 
increase the likelihood of smoking cessation 
(buproprion—RR 1.62, 95% CI: 1.49–1.76; 
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nortriptyline—RR 2.03, 95 %CI: 1.48-2.78) compared 
to placebo (Hughes et al, 2014). Both are considered 
to be equally efective and of similar eicacy as NRT in 
achieving long-term cessation; however, their addition 
to NRT does not provide any additional beneit 
(Hughes et al, 2014). 
Dosing
Varenicline increases the chances of successful smoking 
cessation by more than two- to threefold (OR 2.88, 95% 
CI: 2.40–3.47) at 6 months relative to placebo (Cahill 
et al, 2013). A reduced dosage is efective compared 
to a standard dosage (RR 1.25, 95% CI: 1.00–1.55) 
relative to placebo for long-term smoking cessation. 
A lower dose has fewer and less severe side efects 
and achieves cessation rates roughly similar to NRT 
or bupropion (Cahill et al, 2016). When compared 
to bupropion, varenicline signiicantly increases the 
chances of successful smoking cessation (OR 1.59, 
95% CI: 1.29–1.96) (Cahill et al, 2016). It is also more 
efective than a single form of NRT (OR 1.57, 95% CI 
1.29–1.91), but not more efective than combination 
NRT (OR 1.06, 95% CI 0.75–1.48) (Cahill et al, 2013). 
here is also limited evidence that varenicline might 
have a beneicial role in relapse prevention compared 
to placebo (RR 1.24, 95% CI 1.08–1.42) at 52 weeks 
(Cahill et al, 2016).
he standard dosage of varenicline used in clinical 
trials is 1.0 mg twice a day (Cahill et al, 2016). he 
standard dosage of bupropion in practice is 150 mg 
once a day for 3–6 days, increased to 150 mg twice a 
day to be continued for 7–12 weeks, initiated a week 
before the quit date of the smoker (Hughes et al, 2014).
Side efects
he adverse events with bupropion use include insomnia, 
dry mouth, nausea, and, rarely, seizures (1 in 1000) 
(Hughes et al, 2014). he adverse events reported with 
varenicline use mainly include mild-to-moderate levels of 
nausea. However, there is inconclusive evidence suggesting 
links with serious adverse events including depressed 
mood, agitation, suicidal thinking and cardiovascular 
problems (Cahill et al, 2016). Although, a study from 
homas et al (2013) found that neither varenicline nor 
bupropion increased the risk of fatal or non-fatal self-
harm, or increased the risk of depression treated with 
antidepressants compared with NRT alone.
he use of cytisine is shown to have a beneicial efect 
in achieving smoking cessation compared to placebo 
(RR 3.98, 95% CI 2.07–7.87). Cytisine also demonstrated 
beneit when compared to NRT (RR 1.43, 95% CI 
1.13–1.80) with abstinence rates of 21.8% vs 15.3% at 6 
months (Cahill et al, 2016). Adverse events with cytisine 
use include Gastrointestinal disorders, sleep disorders, 
nausea and vomiting; the rates for these adverse events 
are signiicantly higher than placebo (West et al, 2011) 
and NRT (Walker et al, 2014).
here is insuicient evidence to support the use 
of other antidepressive agents (Monoamine oxidase 
inhibitors, selective serotonin reuptake inhibitors, 
Electronic cigarettes heat a liquid into an aerosol for inhalation. 
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St. John’s wort, venlafaxine, and dietary supplement 
S-adenosyl-L-methionine (SAMe) for smoking cessation 
(Hughes et al, 2014.
Electronic cigarettes
Electronic cigarettes or electronic nicotine delivery 
systems (ENDs) are devices that heat a liquid into an 
aerosol for inhalation. he liquid usually comprises 
propylene glycol and glycerol, with or without 
nicotine and lavours (Boyce et al, 2016). here is 
wide variation between diferent types of electronic 
cigarettes; the more recent generations of electronic 
cigarettes have a very similar nicotine delivery proile 
to combustible cigarettes. 
here has been a steady growth in sales of 
electronic cigarettes since they appeared on the market 
in 2006 (Boyce et al, 2016). Electronic cigarettes are 
considered a less harmful alternative to combustible 
cigarettes and promoted as a tool for harm reduction 
in the UK (McNeill et al, 2015; Britton et al, 2016). 
However, the role and impact of electronic cigarettes 
remain a major public health debate (McNeill et al, 
2015) as there is limited evidence on the long-term 
health efect on active and passive use of e-cigarettes 
(Latif and Nair, 2016). 
A recent Cochrane review showed that using 
electronic cigarettes containing nicotine increased 
the chances of stopping smoking in the long-term 
compared to using an electronic cigarettes without 
nicotine (Boyce et al, 2016). Combined results from 
the two randomised controlled trials also suggest that 
use of a nicotine-containing electronic cigarettes was 
associated with higher abstinence rates than placebo 
electronic cigarettes use (RR 2.29, 95%CI 1.05–4.96) 
(Boyce et al, 2016). However, authors could not 
determine if electronic cigarettes was better than a 
nicotine patch in helping people stop smoking, because 
the number of participants in the study was low. None 
of the studies found that smokers who used electronic 
cigarettes short- to mid-term (for 2 years or less) had an 
increased health risk compared to smokers who did not 
use electronic cigarettes. he authors acknowledged that 
the quality of the evidence overall was low due to the 
small number of studies, although these studies were 
well conducted (Boyce et al, 2016). 
Effective combinations
Behavioural support and pharmacotherapies 
individually aid smokers in successful attempts to stop 
smoking. Many guidelines recommend combining the 
two interventions to assist people in stopping smoking, 
but there are some combinations that are more efective 
than others, and some that work better in certain 
settings than in others.
A combination of behavioural support and 
pharmacotherapy can increase the chances of successful 
smoking cessation by 70–100% (RR 1.83, 95% CI 1.68–
1.98) compared to controls receiving brief advice, usual 
care or less intensive behavioural support (Stead and 
Lancaster, 2016). Combination therapies demonstrate 
a greater beneit when delivered in health-care settings 
(RR 1.97, 95% CI 1.79–2.18) than when used in 
community-based settings (RR 1.53, 95% CI 1.33–1.76) 
(Stead et al, 2016).
Using intensive behavioural support (face-to-face 
or via telephone) as an adjunct to pharmacotherapy 
increases the chances of successful smoking cessation 
by about 10–40% (face-to-face RR 1.12, 95% CI 1.04–
1.20; telephone RR 1.28, 95% CI 1.17–1.41) relative 
to controls using pharmacotherapy alone (Stead et al, 
2015). Moreover, increasing the intensity of behavioural 
support in people attempting to stop smoking with 
pharmacotherapy increases the chances of successful 
smoking cessation by another 10–25% (RR 1.17, 95% CI 
1.11–1.24) relative to less-intensive behavioural support. 
However, there is insuicient evidence to support any 
beneicial efect of behavioural support when added to 
nortriptylin or varenicline (Stead et al, 2015).
Smoking in pregnancy
he addition of NRT to behavioural support may be 
an efective strategy to promote smoking cessation in 
pregnant women (RR 1.41, 95% CI 1.03–1.93); however, 
the interpretation should be made with caution, as the 
efect is lower in placebo randomised controlled trials 
Key Points
 ■ Brief advice by a health professional is beneficial in achieving 
smoking cessation 
 ■ Intensive behavioural support alone and in combination 
with pharmacotherapies is effective in promoting smoking 
cessation
 ■ Pharmacotherapies (nicotine replacement therapy (NRT), 
bupropion, nortriptyline, varenicline and cytisine) are 
individually effective in promoting smoking cessation
 ■ A combination of NRTs (slow and rapid release) are effective 
for promoting cessation among harder smokers
 ■ Combination therapies of behavioural support and 
pharmacotherapy are more effective than pharmacotherapies 
alone in promoting cessation among smokers when delivered 
in health care settings
 ■ There is limited evidence of benefit from electronic cigarettes 
in smoking cessation
Useful resources
 ■ National Institute for Health and Care Excellence (2008) 
Smoking cessation services in primary care, pharmacies, local 
authorities and work places, particularly for manual working 
groups, pregnant women and hard to reach communities. 
NICE, London
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(RR 1.28, 95% CI 0.99–1.66) compared to non-placebo 
randomised controlled trials (Coleman et al, 2015). 
‘Smoking reduction’ vs ‘abrupt cessation’
A reduction in smoking before the quit date and 
stopping abruptly, with no prior reduction, produces 
comparable smoking cessation rates (Lindson‐Hawley 
et al, 2012). Trials using the nicotine-assisted reduction 
to stop (NARS) strategy indicate that it is efective 
(RR 2.06, 95% CI: 1.34–3.15) in achieving sustained 
abstinence in smokers who are otherwise unable to 
attempt an abrupt quit (Moore et al, 2009). 
In addition, smokers who do not wish to quit might 
be helped to cut-down the number of cigarettes they 
smoke and ultimately to quit smoking in the long term 
despite original intentions not to do so (Lindson-
Hawley et al, 2016). NRT is found to be efective in 
reducing the number of daily cigarettes smoked by 50% 
(RR 1.75 95%CI 1.44–2.13) in such users, although 
this was not relected in the carbon monoxide and 
cotinine levels of the users. NRT was also found to 
be efective for long-term smoking quit in these users 
(RR 1.87, 95%CI 1.43–2.44); however, the quality of 
evidence was assessed to be low. here is insuicient 
evidence at this time for the application of other 
methods (pharmacological intervention, electronic 
cigarettes, snus, nicotine patches and low tar cigarettes) 
in demonstrating a smoking reduction or complete 
cessation in smokers unwilling or unable to quit 
(Lindson-Hawley et al, 2016).
Adjunct aids
here is insuicient evidence to suggest a possible 
beneicial role of smoking cessation and weight gain 
therapies in limiting post-cessation weight gain in 
people stopping smoking in the long term (Farley et 
al, 2012) and also of exercise interventions aiming 
to increase cessation rates among smokers (Ussher 
et al, 2014). he role of social support by peer or 
partner in improving smoking cessation rates among 
pregnant women or people attempting to quit 
remains inconclusive due to limited evidence (Park 
et al, 2012). Similarly, although there is evidence of 
a potential beneit from peer support provided to 
pregnant women for smoking cessation (RR 1.09, 
95%CI 1.01–2.19), the evidence at this time is limited 
(Chamberlain et al, 2013).
Conclusions
he research on smoking cessation suggests that 
diferent therapies and their combinations work 
better in certain settings than in others, and need to 
be tailored according to the patient type and their 
preferences. Overall, even brief advice by a trained 
health professional is beneicial in achieving smoking 
cessation in a patient presenting to health services, 
but to a lesser extent than behavioural support 
alone or in combination with pharmacotherapies 
(NRTs, bupropion and varenicline). Individual 
pharmacotherapies are efective for smoking cessation, 
however, they are to be more efective in combination 
with behavioural support. Combination NRTs (oral or 
skin patch) are observed to be particularly helpful in 
promoting cessation among heavy smokers compared 
to light smokers. 
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